Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies
Open Access
- 23 December 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pediatric Research
- Vol. 75 (4), 527-534
- https://doi.org/10.1038/pr.2013.246
Abstract
Phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS) is caused by germ line mutations in the PTEN gene. Symptoms include cancer predisposition, immune deviations, and lipomas/lipomatosis. No causal standard therapy is available. We describe a therapeutic attempt with the mammalian target of rapamycin (mTOR) inhibitor sirolimus for a PHTS patient suffering from thymus hyperplasia and lipomatosis. We furthermore assessed the in vitro effects of sirolimus and other inhibitors on lipoma cells of the patient. The patient underwent clinical and blood examinations and whole-body magnetic resonance imaging to assess tumor sizes. Lipoma cells of the patient were incubated with inhibitors of the phosphoinositide-3-kinase (PI3K)/AKT/mTOR signaling pathway to analyze the effects on proliferation, adipocyte differentiation, and survival in vitro. Sirolimus treatment improved somatic growth and reduced thymus volume. These effects diminished over the treatment period of 19 mo. Sirolimus decreased lipoma cell proliferation and adipocyte differentiation in vitro but did not cause apoptosis. PI3K and AKT inhibitors induced apoptosis significantly. Sirolimus treatment led to an improvement of the patient’s clinical status and a transient reduction of the thymus. Our in vitro findings point to PI3K and AKT inhibitors as potential treatment options for patients with severe forms of PHTS.Keywords
This publication has 24 references indexed in Scilit:
- Lifetime Cancer Risks in Individuals with Germline PTEN MutationsClinical Cancer Research, 2012
- High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1Cell Cycle, 2011
- Pushing the Envelope in the mTOR Pathway: The Second Generation of InhibitorsMolecular Cancer Therapeutics, 2011
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of RapamycinCancer Research, 2009
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)Biochemical Journal, 2009
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJCI Insight, 2008
- Rapamycin treatment for a child with germline PTEN mutationNature Clinical Practice Oncology, 2008
- Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- OsiriX: An Open-Source Software for Navigating in Multidimensional DICOM ImagesJournal of Digital Imaging, 2004
- PTEN: One Gene, Many SyndromesHuman Mutation, 2003